Andersen S - Search Results

1

ACE insertion/deletion genotypes and angiotensin II receptor blockade in diabetic nephropathy: is there a light at the end of the tunnel?

Andersen S, Jacobsen P, Parving HH. Andersen S, et al. Diabetes Care. 2003 Oct;26(10):2962-3. doi: 10.2337/diacare.26.10.2962-a. Diabetes Care. 2003. PMID: 14514616 No abstract available.

2

Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Diabetes Care. 2003 May;26(5):1501-6. doi: 10.2337/diacare.26.5.1501. Diabetes Care. 2003. PMID: 12716812

3

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Jacobsen P, et al. Among authors: andersen s. Nephrol Dial Transplant. 2002 Jun;17(6):1019-24. doi: 10.1093/ndt/17.6.1019. Nephrol Dial Transplant. 2002. PMID: 12032191 Clinical Trial.

4

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Kidney Int. 2002 Jul;62(1):192-8. doi: 10.1046/j.1523-1755.2002.00410.x. Kidney Int. 2002. PMID: 12081578 Free article. Clinical Trial.

5

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.

Jacobsen P, Andersen S, Jensen BR, Parving HH. Jacobsen P, et al. Among authors: andersen s. J Am Soc Nephrol. 2003 Apr;14(4):992-9. doi: 10.1097/01.asn.0000054495.96193.bf. J Am Soc Nephrol. 2003. PMID: 12660333 Clinical Trial.

6

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Jacobsen P, et al. Among authors: andersen s. Kidney Int. 2003 May;63(5):1874-80. doi: 10.1046/j.1523-1755.2003.00940.x. Kidney Int. 2003. PMID: 12675866 Free article. Clinical Trial.

7

Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Andersen S, et al. Diabetes Care. 2003 Dec;26(12):3296-302. doi: 10.2337/diacare.26.12.3296. Diabetes Care. 2003. PMID: 14633817 Clinical Trial.

8

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L. Parving HH, et al. Among authors: andersen s. Semin Nephrol. 2004 Mar;24(2):147-57. doi: 10.1016/j.semnephrol.2003.11.003. Semin Nephrol. 2004. PMID: 15017527 Review.

9

Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy.

Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, van Nieuwenhoven FA. Nguyen TQ, et al. Among authors: andersen s. Diabetes Care. 2006 Jan;29(1):83-8. doi: 10.2337/diacare.29.1.83. Diabetes Care. 2006. PMID: 16373901

10

Optimal dose of losartan for renoprotection in diabetic nephropathy.

Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Andersen S, et al. Nephrol Dial Transplant. 2002 Aug;17(8):1413-8. doi: 10.1093/ndt/17.8.1413. Nephrol Dial Transplant. 2002. PMID: 12147788

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,259 results

Search Page

Filters